Characterization of lymphangioleiomyomatosis patients with discordance between spirometric and diffusion measurements of pulmonary function
- PMID: 32476904
- PMCID: PMC7170150
- DOI: 10.36141/svdld.v35i3.6321
Characterization of lymphangioleiomyomatosis patients with discordance between spirometric and diffusion measurements of pulmonary function
Abstract
Background: A subset of lymphangioleiomyomatosis (LAM) patients present with normal FEV1 and FVC but with reduced DLCO. Patients with an isolated reduction in DLCO in other diseases appear to be at higher risk for pulmonary hypertension and worse survival but this has not been previously described in LAM patients. Objective: To characterize the prevalence and clinical progression of LAM patients who present with discordantly low DLCO. Methods: This was a retrospective cohort study of LAM patients in two centers in the United States and Brazil. Discordant DLCO was defined as FEV1 >80% predicted, FVC >80% predicted, and DLCO<80% predicted. We compared the rate of decline in pulmonary function, pulmonary artery to aorta (PA-A) ratio, and VEGF-D levels in patients with concordant and discordant DLCO. Results: The overall prevalence of discordant DLCO was 26.0%. Patients with discordant DLCO did not have a higher rate of yearly decline in FEV1 (-1.0±0.6 vs -1.0±0.6, p=0.50), FVC (-1.0±0.7 vs -0.3±0.8, p=0.54), or DLCO (-2.2±0.9 vs -1.6±0.6, p=0.79). They did not have higher rates of PA-A ratio>1 (23.3% vs 20.1%, p=1.00). Patients with discordant DLCO did not have higher levels of VEGF-D (1214±1256 pg/mL vs 1706±1214 pg/mL, p=0.07). Conclusions: LAM patients who present with a discordantly low DLCO do not appear to have different rates of decline in pulmonary function. Additional biological and radiographic markers are needed to more fully characterize this population. (Sarcoidosis Vasc Diffuse Lung Dis 2018; 35: 206-212).
Keywords: DLCO; FEV1; VEGF; lymphangioleiomyomatosis; pulmonary artery to aorta ratio.
Copyright: © 2018.
Figures

Similar articles
-
Ultra-Small Lung Cysts Impair Diffusion Without Obstructing Air Flow in Lymphangioleiomyomatosis.Chest. 2021 Jul;160(1):199-208. doi: 10.1016/j.chest.2021.01.077. Epub 2021 Feb 5. Chest. 2021. PMID: 33549601 Free PMC article.
-
Pulmonary hypertension in lymphangioleiomyomatosis: prevalence, severity and the role of carbon monoxide diffusion capacity as a screening method.Orphanet J Rare Dis. 2017 Apr 20;12(1):74. doi: 10.1186/s13023-017-0626-0. Orphanet J Rare Dis. 2017. PMID: 28427470 Free PMC article.
-
Vascular endothelial growth factor-D is increased in serum of patients with lymphangioleiomyomatosis.Lymphat Res Biol. 2006;4(3):143-52. doi: 10.1089/lrb.2006.4.143. Lymphat Res Biol. 2006. PMID: 17034294
-
Decline in lung function in patients with lymphangioleiomyomatosis treated with or without progesterone.Chest. 2004 Dec;126(6):1867-74. doi: 10.1378/chest.126.6.1867. Chest. 2004. PMID: 15596686
-
Office-based DLCO tests help pulmonologists to make important clinical decisions.Respir Investig. 2016 Sep;54(5):305-11. doi: 10.1016/j.resinv.2016.03.006. Epub 2016 May 2. Respir Investig. 2016. PMID: 27566377 Review.
Cited by
-
Lymphangioleiomyomatosis: circulating levels of FGF23 and pulmonary diffusion.J Bras Pneumol. 2023 May 1;49(2):e20220356. doi: 10.36416/1806-3756/e20220356. eCollection 2023. J Bras Pneumol. 2023. PMID: 37132737 Free PMC article.
-
Serum endostatin levels are associated with diffusion capacity and with tuberous sclerosis- associated lymphangioleiomyomatosis.Orphanet J Rare Dis. 2019 Mar 29;14(1):72. doi: 10.1186/s13023-019-1050-4. Orphanet J Rare Dis. 2019. PMID: 30922357 Free PMC article.
References
-
- Steen VD, Graham G, Conte C, Owens G, Medsger TA. Isolated diffusing capacity reduction in systemic sclerosis. Arthrit & Rheum. 1992;35:765–770. - PubMed
-
- Cottin V, Harari S, Humbert M, et al. Pulmonary hypertension in lymphangioleiomyomatosis: characteristics in 20 patients. Euro Resp J. 2012;40:630–640. - PubMed
LinkOut - more resources
Full Text Sources